Product image of Havetra (Enoxaparin Sodium) supplied by GNH India

Havetra

Active Ingredient:
Enoxaparin Sodium
Origin:
EU

Havetra (Enoxaparin Sodium)

Havetra is a pharmaceutical product that contains the active ingredient enoxaparin sodium, a low‑molecular‑weight heparin, supplied in an injectable form for subcutaneous, intravenous, or haemodialysis administration. It is marketed in the European Union as a prescription‑only anticoagulant. Enoxaparin sodium works by enhancing antithrombin III activity, which reduces clot formation by inhibiting factor Xa and, to a lesser extent, factor IIa (thrombin) in clinical practice for patients.

Manufacturer / TM Owner

Chemi S.P.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Havetra is indicated for several anticoagulation purposes in adult patients.

  • Prevention of deep vein thrombosis (DVT) in patients undergoing surgery or prolonged immobilisation.
  • Treatment of acute DVT to reduce clot extension and recurrence.
  • Prevention and treatment of pulmonary embolism (PE) in at‑risk individuals.
  • Anticoagulation during haemodialysis to maintain circuit patency.
  • Prophylaxis of thromboembolic events in patients with acute medical illnesses.

Side Effects

Adverse reactions to Havetra may vary in frequency and severity.

Common

  • Mild bruising, redness, or pain at the subcutaneous injection site.
  • Minor bleeding episodes such as occasional nosebleeds, gum bleeding, or easy bruising.
  • Small localized hematoma formation around the injection area.
  • Transient, mild elevations in liver transaminases observed in some patients.

Serious

  • Life‑threatening bleeding, including intracranial hemorrhage, gastrointestinal bleeding, or postoperative hemorrhage.
  • Heparin‑induced thrombocytopenia (HIT) characterised by a rapid drop in platelet count and paradoxical clotting.
  • Severe hypersensitivity reactions, including rash, urticaria, angioedema, or anaphylactic shock.
  • Rare occurrences of hyperkalaemia or significant drops in blood pressure.

Precautions & Warnings

Before prescribing Havetra, clinicians should evaluate several safety considerations.

  • Assess renal function; dose adjustment may be required in severe impairment.
  • Review patient history for active bleeding, recent surgery, or trauma.
  • Use cautiously in patients with a known history of heparin‑induced thrombocytopenia.
  • Monitor platelet counts regularly during therapy, especially after 5–10 days of treatment.
  • Evaluate concomitant use of other anticoagulants or antiplatelet agents for additive bleeding risk.
  • Consider pregnancy status; safety data are limited.

Avoid Interactions

Havetra can interact with other medicines, affecting anticoagulant effect or bleeding risk.

Avoid

  • Concurrent use with other injectable or oral anticoagulants (e.g., warfarin, dabigatran) unless specifically directed.
  • Combination with potent antiplatelet drugs such as clopidogrel or ticagrelor without monitoring.

Use with caution

  • Non‑steroidal anti‑inflammatory drugs (NSAIDs) or aspirin, which may increase minor bleeding.
  • Certain antibiotics (e.g., cefazolin) that can potentiate anticoagulant activity.
  • Selective serotonin reuptake inhibitors (SSRIs) or other serotonergic agents that may elevate bleeding risk.

Frequently Asked Questions

Havetra contains enoxaparin sodium, which potentiates antithrombin III, leading to inhibition of factor Xa and, to a lesser extent, factor IIa (thrombin), thereby reducing clot formation.

Havetra is used for prevention of deep vein thrombosis, treatment of acute DVT, prevention and treatment of pulmonary embolism, and as an anticoagulant during haemodialysis.

Havetra is a low‑molecular‑weight heparin with more predictable pharmacokinetics, a longer half‑life, and a greater ratio of anti‑Xa to anti‑IIa activity compared with unfractionated heparin.

Common side effects include mild bruising, redness or pain at the injection site, minor bleeding such as nosebleeds or gum bleeding, small hematomas, and occasional mild elevations in liver enzymes.

Serious bleeding may present as unexplained bruising, blood in urine or stool, coughing up blood, severe headache, vision changes, or any signs of intracranial or gastrointestinal hemorrhage.

Renal function should be assessed before dosing; severe renal impairment may require dose reduction or alternative anticoagulation because enoxaparin is cleared renally.

Safety data for Havetra in pregnancy are limited; it should only be used if the potential benefit justifies the potential risk to the fetus and under specialist guidance.

Routine monitoring includes periodic assessment of platelet counts, signs of bleeding, and renal function; anti‑Xa levels may be measured in special populations such as those with severe renal disease.

Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants) and potent antiplatelet agents should be avoided unless specifically indicated and closely monitored.

For haemodialysis, Havetra is given intravenously at a dose calculated based on patient weight and dialysis circuit requirements to maintain adequate anticoagulation during the procedure.

Heparin‑induced thrombocytopenia (HIT) is an immune‑mediated reaction causing a rapid drop in platelets and paradoxical clotting; it can occur with low‑molecular‑weight heparins like enoxaparin, so platelet monitoring is essential.

A subcutaneous dose of Havetra provides anticoagulant activity for approximately 12–24 hours, depending on the dose and individual patient factors.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Enoxaparin Sodium

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT